SAGE
- Sage Therapeutics, Inc.
()
Overview
Company Summary
Sage Therapeutics, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of novel medicines for the treatment of central nervous system (CNS) disorders. The company aims to fill unmet medical needs and improve the lives of patients suffering from various neurological and psychiatric conditions.
Sage Therapeutics primarily concentrates on developing medicines that target GABA and NMDA receptors in the brain. GABA receptors help in inhibiting neural activity, while NMDA receptors play a role in controlling synaptic plasticity and the communication between neurons.
The company has developed a proprietary drug platform called Positive and Negative Allosteric Modulators (PANAMs). PANAMs are small molecules that modulate the activity of GABA and NMDA receptors to restore balance in the brain for the treatment of CNS disorders.
Sage Therapeutics' lead product candidate is called ZULRESSO� (brexanolone), which is targeted for postpartum depression (PPD) - a severe form of depression that affects women after giving birth. ZULRESSO was approved by the U.S. Food and Drug Administration (FDA) in 2019 and is administered as a continuous intravenous infusion over a defined time period.
The company also has other candidate drugs in various stages of clinical development for different indications, such as major depressive disorder (MDD), essential tremor, Parkinson's disease, and potential applications for certain epileptic disorders.
In summary, Sage Therapeutics specializes in developing and commercializing innovative therapies to target CNS disorders, focusing on GABA and NMDA receptor modulation. Their aim is to provide effective treatments for patients suffering from conditions like postpartum depression and other neurological disorders with limited therapeutic options.